Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (11 quarters reported)
$121M in Q4 2023 → $269M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Delcath Systems, Inc. | 15.4% | Unchanged | 3,300,389 | $41.6M |
| Fennec Pharmaceuticals Inc | 12.7% | Added 9.6% | 3,188,001 | $34.3M |
| Xeris Biopharma Holdings Inc | 8.6% | Trimmed 10.0% | 2,908,981 | $23M |
| Savara Inc | 7.3% | Trimmed 0.8% | 3,178,121 | $19.6M |
| Verastem Inc | 5.7% | Added 86% | 3,986,509 | $15.2M |
| X4 Pharmaceuticals Inc | 5.6% | Unchanged | 3,214,766 | $15M |
| EP Eyepoint Pharmaceuticals Inc | 5.2% | Trimmed 4.7% | 988,230 | $14.1M |
| Cybin Inc | 4.8% | Added 28% | 1,956,814 | $12.9M |
| Vor Biopharma Inc | 4.4% | Trimmed 7.3% | 648,600 | $11.9M |
| Vaxcyte Inc | 4.3% | Trimmed 31% | 200,000 | $11.6M |
| Mediwound Ltd | 4.1% | Unchanged | 749,054 | $11M |
| Celldex Therapeutics Inc | 2.8% | Trimmed 39% | 200,000 | $7.44M |
| Biocryst Pharmaceuticals Inc | 2.7% | Trimmed 22% | 721,504 | $7.22M |
| Profound Medical Corp | 2.0% | Unchanged | 828,118 | $5.51M |
| Talphera Inc | 2.0% | Added 54% | 5,169,501 | $5.32M |
| Atea Pharmaceuticals Inc | 1.8% | Trimmed 8.6% | 1,070,550 | $4.98M |
| Myomo Inc | 1.4% | Trimmed 5.4% | 3,637,886 | $3.78M |
| Ovid Therapeutics Inc | 1.1% | Unchanged | 1,107,994 | $2.98M |
| Neuraxis Inc | 1.1% | Added 78% | 508,055 | $2.97M |
| Abivax Sa | 1.0% | New | 20,869 | $2.78M |
| Inspiremd Inc | 1.0% | Unchanged | 3,905,743 | $2.73M |
| RB Regentis Biomaterials Ltd | 0.9% | Added 179% | 701,685 | $2.48M |
| Sellas Life Sciences Group Inc Put | 0.9% | New | 568,700 | $2.3M |
| Polypid Ltd | 0.7% | Trimmed 35% | 389,455 | $1.98M |
| Biofrontera Inc | 0.4% | Added 9.6% | 1,275,609 | $1.21M |
| Kura Oncology Inc | 0.4% | Unchanged | 100,000 | $1.1M |
| Spruce Biosciences Inc | 0.4% | New | 20,000 | $1.08M |
| Aquestive Therapeutics Inc | 0.4% | Unchanged | 250,000 | $1.04M |
| Onkure Therapeutics Inc | 0.3% | Trimmed 66% | 150,000 | $684K |
| Pepgen Inc | 0.2% | New | 350,000 | $630K |
| Cg Oncology Inc Call | 0.1% | New | 31,000 | $375K |
| EP Eyepoint Pharmaceuticals Inc Call | 0.0% | New | 50,300 | $131K |
| IT Ishares Tr Put | 0.0% | New | 500,000 | $110K |
| SS SPDR Series Trust Put | 0.0% | New | 140,600 | $35.2K |
| Tenax Therapeutics Inc Put | 0.0% | New | 6,200 | $14K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Verastem Inc | Added | +1,848,034 | +$7.06M | 5.7% |
| Cg Oncology Inc | Exited | −100,000 | −$6.77M | — |
| Vaxcyte Inc | Trimmed | −90,000 | −$5.23M | 4.3% |
| Viridian Therapeutics Inc | Exited | −250,401 | −$4.9M | — |
| Celldex Therapeutics Inc | Trimmed | −130,000 | −$4.84M | 2.8% |
| Fennec Pharmaceuticals Inc | Added | +279,800 | +$3.01M | 12.7% |
| Cybin Inc | Added | +425,000 | +$2.81M | 4.8% |
| Abivax Sa | New | +20,869 | +$2.78M | 1.0% |
| Replimune Group Inc | Exited | −1,275,600 | −$2.75M | — |
| Xeris Biopharma Holdings Inc | Trimmed | −322,719 | −$2.56M | 8.6% |
Showing the 10 largest of 39 changes.
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vaxcyte Inc | New | +290,000 | +$16.9M | 6.8% |
| Replimune Group Inc | Exited | −1,410,497 | −$13.7M | — |
| Astria Therapeutics Inc | Exited | −1,039,080 | −$13.6M | — |
| Cg Oncology Inc | Trimmed | −200,000 | −$13.5M | 2.7% |
| Vor Biopharma Inc | New | +700,000 | +$12.5M | 5.0% |
| Cytokinetics Inc | Exited | −195,045 | −$12.4M | — |
| Celldex Therapeutics Inc | New | +330,000 | +$10.5M | 4.2% |
| MM Mind Medicine Mindmed Inc | Exited | −750,000 | −$10M | — |
| Biocryst Pharmaceuticals Inc | New | +923,057 | +$8.79M | 3.5% |
| Xeris Biopharma Holdings Inc | Added | +1,120,000 | +$6.5M | 7.5% |
Showing the 10 largest of 48 changes.
quarter ended December 31, 2025 · filed February 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rezolute Inc | Exited | −1,807,202 | −$17M | — |
| Replimune Group Inc | New | +1,410,497 | +$13.7M | 4.8% |
| Cytokinetics Inc | Trimmed | −204,955 | −$13M | 4.4% |
| Verona Pharma PLC | Exited | −100,000 | −$10.7M | — |
| Fractyl Health Inc | Trimmed | −4,614,269 | −$10.2M | 0.3% |
| Ideaya Biosciences Inc | Exited | −350,000 | −$9.52M | — |
| UN Uniqure Nv | Exited | −125,000 | −$7.3M | — |
| Viridian Therapeutics Inc | Trimmed | −150,000 | −$4.67M | 4.9% |
| Atyr Pharma Inc | Exited | −1,570,200 | −$4.47M | — |
| Arrivent Biopharma Inc | New | +215,871 | +$4.34M | 1.5% |
Showing the 10 largest of 38 changes.
quarter ended September 30, 2025 · filed November 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ocular Therapeutix Inc | Trimmed | −818,700 | −$9.57M | 1.6% |
| EP Eyepoint Pharmaceuticals Inc | New | +650,000 | +$9.26M | 3.2% |
| Replimune Group Inc | Exited | −900,000 | −$8.36M | — |
| Fractyl Health Inc | New | +5,000,000 | +$7.95M | 2.7% |
| Atyr Pharma Inc | New | +1,039,080 | +$7.56M | 2.6% |
| Urogen Pharma Ltd | Exited | −542,366 | −$7.43M | — |
| UN Uniqure Nv | New | +125,000 | +$7.3M | 2.5% |
| Mediwound Ltd | Added | +341,993 | +$6.16M | 4.6% |
| X4 Pharmaceuticals Inc | New | +1,544,607 | +$5.28M | 1.8% |
| Savara Inc | Added | +1,345,056 | +$4.8M | 4.9% |
Showing the 10 largest of 43 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cytokinetics Inc | New | +400,000 | +$13.2M | 6.3% |
| Abeona Therapeutics Inc | Exited | −1,805,817 | −$8.6M | — |
| Rezolute Inc | New | +1,741,211 | +$7.77M | 3.7% |
| Urogen Pharma Ltd | Trimmed | −407,634 | −$5.58M | 3.5% |
| Cg Oncology Inc | New | +192,974 | +$5.02M | 2.4% |
| Nuvation Bio Inc | Exited | −2,451,500 | −$4.31M | — |
| DS Delcath Sys Inc | Added | +400,000 | +$4M | 15.6% |
| Ideaya Biosciences Inc | Trimmed | −188,868 | −$3.97M | 5.1% |
| Verastem Inc | Trimmed | −600,954 | −$2.49M | 4.0% |
| Optinose Inc | Exited | −256,190 | −$2.35M | — |
Showing the 10 largest of 37 changes.
quarter ended March 31, 2025 · filed May 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ideaya Biosciences Inc | New | +700,000 | +$11.5M | 5.6% |
| Chimerix Inc | Exited | −3,050,000 | −$10.6M | — |
| Verastem Inc | Added | +1,744,517 | +$10.5M | 7.8% |
| Viridian Therapeutics Inc | New | +595,000 | +$8.02M | 3.9% |
| Replimune Group Inc | Added | +590,000 | +$5.75M | 4.0% |
| Optinose Inc | Trimmed | −620,806 | −$5.69M | 1.1% |
| Nuvation Bio Inc | New | +2,451,500 | +$4.31M | 2.1% |
| CS Cassava Sciences Inc | Exited | −417,400 | −$3.65M | — |
| Pharvaris N V | New | +223,627 | +$3.51M | 1.7% |
| Xeris Biopharma Holdings Inc | Trimmed | −609,009 | −$3.34M | 6.7% |
Showing the 10 largest of 41 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cormedix Inc | Exited | −1,475,000 | −$11.9M | — |
| Chimerix Inc | New | +3,050,000 | +$10.6M | 5.4% |
| Cybin Inc | Exited | −1,075,105 | −$9.56M | — |
| Urogen Pharma Ltd | New | +870,000 | +$9.27M | 4.7% |
| Savara Inc | New | +2,654,944 | +$8.15M | 4.2% |
| Fennec Pharmaceuticals Inc | New | +1,259,876 | +$7.96M | 4.1% |
| Cellectar Biosciences Inc | Exited | −3,671,550 | −$7.86M | — |
| Cybin Inc | New | +810,918 | +$7.15M | 3.7% |
| Optinose Inc | New | +876,996 | +$5.86M | 3.0% |
| Verona Pharma PLC | Trimmed | −125,000 | −$5.81M | 3.6% |
Showing the 10 largest of 51 changes.
quarter ended September 30, 2024 · filed October 30, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cybin Inc | Trimmed | −18,224,895 | −$162M | 6.1% |
| Cormedix Inc | New | +1,475,000 | +$11.9M | 7.6% |
| Viridian Therapeutics Inc | Exited | −300,000 | −$3.9M | — |
| Cormedix Inc | New | +700,000 | +$3.64M | 2.3% |
| Clearside Biomedical Inc | Trimmed | −2,465,373 | −$3.13M | 0.1% |
| Abivax Sa | Trimmed | −238,433 | −$2.75M | 1.0% |
| Trevi Therapeutics Inc | Trimmed | −641,577 | −$2.14M | 1.6% |
| Mediwound Ltd | Added | +114,560 | +$2.07M | 7.3% |
| Cellectar Biosciences Inc | Added | +965,934 | +$2.07M | 5.0% |
| CS Cassava Sciences Inc | Added | +363,727 | +$1.44M | 0.9% |
Showing the 10 largest of 40 changes.
Loading...
